December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Ponatinib treatment in patient with chronic-phase chronic myeloid leukemia who progressed after second-generation TKIs showed efficacy and tolerability in this pooled analysis of the PACE and OPTIC trials.